News

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Vinay Prasad has stepped down as head of the FDA’s biologics division just two months into the job, following growing ...
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...